Kenvue (NYSE:KVUE) Given New $19.00 Price Target at Barclays

Kenvue (NYSE:KVUE) had its target price hoisted by Barclays from $18.00 to $19.00 in a report issued on Friday,Benzinga reports. Barclays currently has an equal weight rating on the stock.

Other analysts also recently issued reports about the company. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the stock from $23.00 to $18.00 in a research report on Friday, January 30th. Citigroup increased their price objective on shares of Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, February 18th. UBS Group upped their target price on shares of Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a research note on Wednesday, February 18th. Finally, Canaccord Genuity Group raised their price target on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. Three investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $19.58.

Kenvue Trading Up 0.9%

KVUE stock traded up $0.16 during midday trading on Friday, reaching $18.41. 19,034,355 shares of the company’s stock traded hands, compared to its average volume of 44,677,640. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. Kenvue has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The business has a 50-day moving average price of $17.85 and a two-hundred day moving average price of $17.45. The company has a market capitalization of $35.29 billion, a P/E ratio of 23.91, a PEG ratio of 4.18 and a beta of 0.51.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.05. The company had revenue of $3.78 billion during the quarter, compared to analyst estimates of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.26 earnings per share. Equities research analysts forecast that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th were given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.5%. The ex-dividend date of this dividend was Wednesday, February 11th. Kenvue’s dividend payout ratio is presently 107.79%.

Insider Activity at Kenvue

In other Kenvue news, Director Jeffrey C. Smith bought 3,200,000 shares of Kenvue stock in a transaction dated Friday, December 12th. The stock was bought at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the purchase, the director owned 27,307,632 shares in the company, valued at $474,333,567.84. This represents a 13.27% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.68% of the company’s stock.

Institutional Trading of Kenvue

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank acquired a new position in Kenvue during the 4th quarter worth $756,862,000. Independent Franchise Partners LLP lifted its position in shares of Kenvue by 233.4% during the second quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after purchasing an additional 21,886,537 shares during the last quarter. Sculptor Capital LP lifted its position in shares of Kenvue by 1,023.5% during the fourth quarter. Sculptor Capital LP now owns 12,886,328 shares of the company’s stock worth $222,289,000 after purchasing an additional 11,739,328 shares during the last quarter. Capitolis Liquid Global Markets LLC grew its stake in Kenvue by 1,116.8% in the fourth quarter. Capitolis Liquid Global Markets LLC now owns 10,950,999 shares of the company’s stock worth $188,905,000 after purchasing an additional 10,050,999 shares in the last quarter. Finally, Cibc World Markets Corp acquired a new position in Kenvue in the fourth quarter worth about $162,193,000. Institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.